title: T-cell receptor Vbeta repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
abstract: T cells play an important role in the adaptive immune system. After haematopoietic stem cell transplantation (HSCT), T-cell function is impaired. This is reflected by the emergence of opportunistic infections, infections that are often difficult to treat because of the patient's insufficient immune function. T-cell receptor reconstitution was studied using CDR3 spectratyping to analyze the diversity of the T-cell repertoire at 3, 6 and 12 months after myeloablative and reduced intensity conditioning (RIC) HSCT in 23 patients. Immune function in vitro was tested by lymphocyte stimulation at 3, 6 and 12 months after HSCT. Lower diversity in the CDR3 repertoire was demonstrated in CD4+ cells after RIC HSCT at 3 and 6 months and in CD8+ cells at 3 months compared with healthy donors. After myeloablative HSCT, lower diversity was seen at 3, 6 and 12 months in CD4+ cells and at 6 and 12 months in CD8+ cells after HSCT. Acute and chronic graft-versus-host-disease (GVHD) did not affect diversity. Responses to phytohaemagglutinin (PHA), Concanavalin A (Con A) and Staphylococcus aureus protein A were significantly lower compared with healthy donors during the first 6 months after RIC HSCT. After myeloablative HSCT, lymphocyte response to Con A was significantly lower at 3 months compared with healthy donors. Decreased responses to cytomegalovirus and varicella zoster virus antigens were seen in patients suffering from acute GVHD grade II or chronic GVHD. The T-cell repertoire is skewed under the first year after HSCT, and immune reconstitution after HSCT with myeloablative and RIC conditioning seems to be comparable. GVHD, infections and age are more important for immune reconstitution than type of conditioning.
authors.affiliation: Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden. patrik.hentschke@karolinska.se
authors.forename: P
authors.initials: P
authors.lastname: Hentschke
authors.forename: B
authors.initials: B
authors.lastname: Omazic
authors.forename: J
authors.initials: J
authors.lastname: Mattsson
authors.forename: I
authors.initials: I
authors.lastname: Näsman-Björk
authors.forename: I
authors.initials: I
authors.lastname: Lundkvist
authors.forename: D
authors.initials: D
authors.lastname: Gigliotti
authors.forename: L
authors.initials: L
authors.lastname: Barkholt
authors.forename: O
authors.initials: O
authors.lastname: Ringdén
authors.forename: M
authors.initials: M
authors.lastname: Remberger
mesh_terms: D000328:Adult; D000941:Antigens / Q000008:administration & dosage; D001483:Base Sequence; D002678:Chimera / Q000235:genetics / Q000276:immunology; D022801:Complementarity Determining Regions / Q000235:genetics; D004247:DNA / Q000235:genetics; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D008934:Mitogens / Q000494:pharmacology; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics*; D013601:T-Lymphocytes / Q000276:immunology; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000941:Antigens; D022801:Complementarity Determining Regions; D008934:Mitogens; D016693:Receptors, Antigen, T-Cell, alpha-beta; D004247:DNA